Abstract Number: 2423 • ACR Convergence 2025
Clinical and Sociodemographic Factors Associated with Diagnostic Delays in Pediatric Lupus Patients
Background/Purpose: Early recognition and treatment of juvenile systemic lupus erythematosus (jSLE) improves outcomes and prevents disease-related mortality. This study examines the contributions of clinical factors…Abstract Number: 0221 • ACR Convergence 2025
A Multimodal Intervention Improves the Quantity and Quality of Disease Activity Measures Collection in a Multi-Centered National Rheumatoid Arthritis Network
Background/Purpose: Clinical guidelines recommend the use of disease activity measures (DAMs) in rheumatoid arthritis (RA) management. Measurement of DAMs is also a critical component of…Abstract Number: 0443 • ACR Convergence 2025
Association between pan-immune-inflammation and synovitis as assessed by ultrasound in rheumatoid arthritis
Background/Purpose: The pan-immune-inflammation value (PIV) is a novel composite biomarker derived from blood count parameters, reflecting the systemic balance of immune-inflammatory activity. Although it has…Abstract Number: 0778 • ACR Convergence 2025
Clinical significance of non-infectious increased procalcitonin in Still’s disease: A predictor of macrophage activation syndrome
Background/Purpose: Still's disease (SD) is a autoinflammatory disease (AID) characterized by a wide range of clinical manifestations and can exhibit life-threatening macrophage activation syndrome (MAS).…Abstract Number: 1028 • ACR Convergence 2025
Enhanced Assessment of Psoriatic Arthritis Disease Progression Using cDAPSA plus the Contrast of Patient Reported Pain and Global Assessment versus Joint Counts
Background/Purpose: The clinical Disease Activity in Psoriatic Arthritis (cDAPSA) score is widely used to assess PsA disease activity and its trajectory. cDAPSA sums four measures:…Abstract Number: 1332 • ACR Convergence 2025
Mid‐Infrared Spectroscopy for Enhanced Diagnosis of Rheumatic Diseases
Background/Purpose: Spectral analysis of liquid biopsies has recently emerged as a promising, non-invasive approach to improve the diagnosis of various pathologies. Our objective was to…Abstract Number: 1491 • ACR Convergence 2025
Feasibility of Extrarenal Systemic Lupus Erythematosus Disease Modification in GLADEL 2.0, a Latin American Cohort
Background/Purpose: The concept of disease modification (DM) has been recently introduced to improve the long-term care of patients (pts) with SLE. DM is defined as…Abstract Number: 1769 • ACR Convergence 2025
Classification of Relapses of Eosinophilic Granulomatosis with Polyangiitis After Two-Years of Treatment with Anti-Interleukin-5/Receptor Therapy
Background/Purpose: Results from the ongoing open-label extension (OLE) of the MANDARA trial (NCT04157348) have demonstrated the efficacy of two years of anti-interleukin-5/receptor (anti-IL-5/R) therapies in…Abstract Number: 2278 • ACR Convergence 2025
Neuroimmune modulation for the Treatment of Rheumatoid Arthritis: Results at 12 months from a Randomized, Sham-Controlled, Double-Blind Study
Background/Purpose: Neuroimmune modulation by electrical stimulation of the left cervical vagus nerve represents a novel treatment option for rheumatoid arthritis (RA). We present 12-month efficacy…Abstract Number: 2430 • ACR Convergence 2025
Disease Activity Independently Correlates with Cognitive Impairment in Systemic Lupus Erythematosus
Background/Purpose: Mechanisms driving cognitive impairment (CI) in systemic lupus erythematosus (SLE) remain poorly understood; conflicting results exist regarding the relationship between CI and disease activity.…Abstract Number: 0222 • ACR Convergence 2025
Evaluating the Barriers and Facilitators for Collecting and Documenting Rheumatoid Arthritis Disease Activity Measures Using a Rheumatology Provider Survey
Background/Purpose: Collection of disease activity measures (DAMs) is a key component of high-quality care for rheumatoid arthritis (RA) patients. This study surveyed rheumatology providers at…Abstract Number: 0444 • ACR Convergence 2025
Low Disease Activity: Good Enough?
Background/Purpose: Treat-to-target is the guiding principle and therapeutic strategy for rheumatoid arthritis (RA) treatment. Escalation of treatment is based on the regular assessment of disease…Abstract Number: 0791 • ACR Convergence 2025
Disagreements in Disease Activity Measures in an Evaluation of SLE Outcome Measures in Telemedicine
Background/Purpose: We previously described the top-line results of our study and the high correlations between virtual SLE disease activity measures (DAM) and those obtained during…Abstract Number: 1070 • ACR Convergence 2025
Cervical Cancer and HPV Screening in Women with Lupus vs Healthy Control Group: A Retrospective Study at a Tertiary Referral Center
Background/Purpose: Women with SLE are at an increased risk of developing cervical cancer, primarily by human papillomavirus (HPV) and immunosuppression. This elevated risk has been…Abstract Number: 1336 • ACR Convergence 2025
Effectiveness of new initiators of tofacitinib and other biologic/targeted synthetic DMARDs in patients with rheumatoid arthritis
Background/Purpose: Though the efficacy and safety profile of tofacitinib in RA has been established in prior trials, the effectiveness of tofacitinib in routine care settings…
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- 6
- …
- 112
- Next Page »